Incyte Corp. stock rises Monday, still underperforms market
Shares of Incyte Corp. INCY rose 1.39% to $62.78 Monday, on what proved to be an all-around positive trading session for the ...
Incyte Had a Bad Week. Investors Are Used to It.
Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...
Incyte price target lowered to $65 from $69 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...
Incyte (INCY) was downgraded to a Hold Rating at William Blair
Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...
Clinical Trials Arena on MSN4d
Incyte stock hit by 11% despite paediatric dermatology trials hitting target
The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
Managed Healthcare Executive19h
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...
Incyte price target lowered to $72 from $74 at Truist
Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Incyte Corp. stock underperforms Monday when compared to competitors
Shares of Incyte Corp. INCY slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the ...
Fierce Biotech7d
Incyte posts phase 3 skin condition wins but details disappoint, sinking stock
Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...
Yahoo Finance3d
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's ...